Citadel Advisors’s Applied Molecular Transport AMTI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-23,576
Closed -$9.9K – 15829
2022
Q4
$9.9K Sell
23,576
-180,086
-88% -$181K ﹤0.01% 13656
2022
Q3
$198K Sell
203,662
-115,903
-36% -$205K ﹤0.01% 10413
2022
Q2
$930K Buy
319,565
+229,114
+253% +$963K ﹤0.01% 7194
2022
Q1
$680K Sell
90,451
-95,881
-51% -$794K ﹤0.01% 8642
2021
Q4
$2.6M Buy
186,332
+13,325
+8% +$263K ﹤0.01% 5620
2021
Q3
$4.48M Buy
+173,007
New +$5.48M ﹤0.01% 4519
2020
Q3
– Sell
-717,330
Closed -$18M – 10940
2020
Q2
$18M Buy
+717,330
New +$18.1M 0.01% 1594

Other funds holding AMTI

Citadel Advisors's AMTI Position: Q1 2023 in Review

Citadel Advisors sold out of Applied Molecular Transport (AMTI) in Q1 2023, closing a stake of 23,576 shares — an estimated $9.9K sold.

Citadel Advisors first reported a position in AMTI in Q2 2020 and held it in 7 quarters. The position peaked at $18M in Q2 2020. 35 funds tracked by Wall St. Rank hold AMTI as of Q1 2023.

  • Citadel Advisors reported no remaining Applied Molecular Transport position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 23,576 Applied Molecular Transport shares in Q1 2023, an estimated $9.9K.
  • Citadel Advisors first reported a position in Applied Molecular Transport in Q2 2020 and held it in 7 quarters.
  • Citadel Advisors's Applied Molecular Transport position peaked at $18M in Q2 2020.
  • 35 funds tracked by Wall St. Rank held Applied Molecular Transport as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.